I-Mab Announces Upcoming Participation at September Conferences

Rhea-AI Summary

I-Mab announces its participation in two upcoming conferences in September 2023, where management will give presentations and hold meetings. The conferences are the H.C. Wainwright 25th Annual Global Investment Conference and the 2023 Cantor Global Healthcare Conference.

ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its participation in the following conferences in September 2023. Details of the conferences and management presentation are as follows:

H.C. Wainwright 25^th Annual Global Investment Conference (Hybrid)

Presentation: Monday, September 11^th at 11:30 a.m. E.S.T

Presenter: Mr. Raj Kannan, CEO

One-on-one and small group meetings: Sept 11-13, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; Dr. Andrew Zhu, President and Head of R&D; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your H.C. Wainwright representative.

2023 Cantor Global Healthcare Conference (In Person)

Presentation: Thursday, September 28^th at 2:25 p.m. E.S.T.

Presenter: Mr. Raj Kannan, CEO; and Dr. John Hayslip, CMO

One-on-one and small group meetings: Sept 26-28, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Cantor representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.

I-Mab Contacts

Investors	Media
Tyler Ehler	Gigi Feng
Senior Director, Investor Relations	Chief Communications Officer
IR@i-mabbiopharma.com	PR@i-mabbiopharma.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-september-conferences-301917513.html

SOURCE I-Mab

FAQ

What conferences is I-Mab participating in September 2023?

I-Mab is participating in the H.C. Wainwright 25th Annual Global Investment Conference and the 2023 Cantor Global Healthcare Conference.

Who will be presenting at the conferences?

Mr. Raj Kannan, CEO, and Dr. John Hayslip, CMO, will be presenting at both conferences.

What are the dates and times of the presentations?

The presentation at the H.C. Wainwright conference will be on Monday, September 11th at 11:30 a.m. E.S.T. The presentation at the Cantor conference will be on Thursday, September 28th at 2:25 p.m. E.S.T.

Will there be one-on-one meetings available?

Yes, one-on-one and small group meetings will be held during the conferences.

Who are the management participants?

The management participants include Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; Dr. Andrew Zhu, President and Head of R&D; and Mr. Tyler Ehler, Senior Director, Investor Relations.